secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073509
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q4 revenue $112M (+46% YoY); Furoscix adds $23M in first quarter
-------------------------------------------------------------------------

- Total revenues $112M in Q4 2025, up 46% vs Q4 2024; full-year revenues $349M, up 22%.
- Afrezza net sales $23M in Q4, +25% YoY; Furoscix net sales $23M since acquisition Oct 7, 2025.
- PDUFA target dates: Afrezza pediatric sBLA May 29, 2026; Furoscix ReadyFlow sNDA July 26, 2026.
- R&D expense $27.6M (+148% YoY); SG&A $58.4M (+144%) driven by Furoscix and launch prep.
- Cash & investments $176M at Dec 31, 2025; scPharmaceuticals acquisition completed Oct 7.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/0001193125-26-073509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer